GlassScriptPhysician profile
Daniel Richard Lewis
NPI 1598749079
$3,436.10
in general payments reported to CMS, 2019-2025
46 companies · $1,455 in 2025
The $1,455 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.02 · 2021: $51.85 · 2022: $182 · 2023: $502 · 2024: $1,213 · 2025: $1,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,169.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $357.67 | 2023-2025 | Tecvayli, Darzalex, Rybrevant |
| Daiichi Sankyo INC. | $260.25 | 2023-2025 | Enhertu, Injectafer, Vanflyta |
| Genentech USA, INC. | $201.53 | 2023-2025 | Venclexta, Polivy, Phesgo |
| Novartis Pharmaceuticals Corporation | $199.41 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $187.49 | 2021-2025 | Tagrisso, Calquence, Enhertu |
| Exelixis INC. | $166.90 | 2023-2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $164.84 | 2023-2025 | Alunbrig, Iclusig, Fruzaqla |
| Abbvie INC. | $164.53 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $143.19 | 2022-2025 | Opdualag |
| Seagen INC. | $125.26 | 2019-2023 | Tivdak |
| Pfizer INC. | $121.91 | 2023-2025 | |
| Celgene Corporation | $120.18 | 2023-2025 | Reblozyl, Opdualag |
| Glaxosmithkline, LLC. | $103.89 | 2023-2025 | Ojjaara, Blenrep |
| Emd Serono, INC. | $79.12 | 2024-2025 | |
| Stemline Therapeutics INC. | $78.51 | 2024-2025 | Orserdu |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.